Announcement
NeuroSearch A/S' share capital and voting rights
As stated in NeuroSearch announcement no 09-08, NeuroSearch increased its share
capital on 11 March 2008 by DKK 265,800 nominal value with the issue of 13,290
new shares of DKK 20 nominal value each, following the exercise of warrants
issued to employees and management in 2004.
Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers'
Disclosure Obligations, it is hereby announced that at the end of March 2008,
the total nominal value of NeuroSearch A/S' share capital is DKK 308,834,640
made up of 15,441,732 shares with a nominal value of DKK 20 each and
corresponding to 308,834,640 votes.
Asger Aamund
Chairman of the Board
Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with
Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as
well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in
collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with
GSK, ACR343 in Parkinson's disease (Phase I) and NSD-788 in anxiety a.o. In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.
